Skeletal muscle atrophy induced by intramuscular repeated dose of botulinum toxin type A in rats

Drug and Chemical Toxicology

Volumn 30, Issue 3, 2007, Pages 217-227

  Choi, Woo H ^a   Song, Chang W ^a   Kim, Yong B ^a   Ha, Chang S ^a   Yang, Gi H ^b   Woo, Hee D ^b   Jung, Hyun H ^b,c   Koh, Woo S ^a  

^a Korea Institute of Toxicology   (South Korea)

^b Medy Tox Inc   (South Korea)

^c SunMoon University   (South Korea)

Author keywords

Botulinum toxin; Muscle atrophy; Repeated dose; Toxicity

Indexed keywords

BOTULINUM TOXIN A; CREATININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; FEMALE; MALE; MUSCLE ATROPHY; NONHUMAN; RAT; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES, BACTERIAL; BODY WEIGHT; BOTULINUM TOXIN TYPE A; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; GAIT; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE FIBERS; MUSCULAR ATROPHY; NEUROMUSCULAR AGENTS; QUADRICEPS MUSCLE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 34347390203     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540701375091     Document Type: Article

References (13)

1. Aoki, K. R. (2001). A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon. 39:1815-1820.
2. Aoki, K. R. (2002). Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon. 40:923-928.
3. Costa, J., Espirito-Santo, C., Borges, A., Ferreira, J. J., Coelho, M., Moore, P., Sampaio, C. (2005). Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst. Rev. CD003633.
4. Dutton, J. J. (1996). Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv. Ophthalmol. 41:51-65.
5. Ghosh, B., Das, S. K. (2002). Botulinum toxin: a dreaded toxin for use in human being. J. Indian Med. Assoc. 100:607-608, 610-602, 614.
6. Huang, W., Foster, J. A., Rogachefsky, A. S. (2000). Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. 43:249-259.
7. Kang, B. H., Son, H.-Y., Ha, C. S., Lee, H.-S., Song, S.-W. (1995). Reference values of hematology and serum chemistry in Ktc:Sprague-Dawley rats. Korean J. Lab. Anim. Sci. 11:141-145.
8. McLellan, K., Das, R. E., Ekong, T. A., Sesardic, D. (1996). Therapeutic botulinum type A toxin: factors affecting potency. Toxicon. 34:975-985.
9. Montecucco, C., Schiavo, G. (1994). Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13:1-8.
10. Nolan, K. W., Cole, L. L., Liptak, G. S. (2006). Use of botulinum toxin type A in children with cerebral palsy. Phys. Ther. 86:573-584.
11. Rosales, R. L., Bigalke, H., Dressler, D. (2006). Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol. 13 (Suppl 1):2-10.
12. Yohio, T. (1989). Biological reference data book on experimental animals. Soft Science, Inc., (Tokyo).
13. Zesiewicz, T. A., Stamey, W., Sullivan, K. L., Hauser, R. A. (2004). Botulinum toxin A for the treatment of cervical dystonia. Expert Opin. Pharmacother. 5:2017-2024.